IFITM3 is critical for limiting the severity of influenza virus infections in humans and mice. Optimal antiviral activity of IFITM3 is achieved when it is present at high levels within cells. Our results indicate that the E3 ubiquitin ligase NEDD4 decreases baseline IFITM3 levels by ubiquitinating IFITM3 and promoting its turnover. Depleting NEDD4 from cells results in IFITM3 accumulation and greater resistance to infection by influenza viruses.

A nanocapsule that dissolves blood clots very fast and can be administered without specialised equipment promises to be the next revolution in treatment of heart attacks and strokes, says a study.

The outbreak of Ebola fever in Guinea, Liberia and Sierra Leone, which has killed more than 11,000 people, has dropped out of the news as it has been brought under control.

In 1996, the global HIV community gathered in Vancouver, Canada, for the XI International AIDS Conference and shared the clear evidence that triplecombination antiretroviral treatment held the power to stem the tide of deaths from AIDS. The HIV treatment era had begun. As we gathered again in Vancouver in July, 2015, it was clear that a new transformative moment is upon us.

The objective of the study was to investigate the association between use of combined oral contraceptives and risk of venous thromboembolism, taking the type of progestogen into account.

Original Source

A new drug compound could lead to a breakthrough in the fight against bovine spongiform encephalopathy, the incurable brain-wasting disease also known as mad cow disease, researchers said Wednesday

A novel Ebola virus (EBOV) first identified in March 2014 has infected more than 25,000 people in West Africa, resulting in more than 10,000 deaths. Preliminary analyses of genome sequences of 81 EBOV collected from March to June 2014 from Guinea and Sierra Leone suggest that the 2014 EBOV originated from an independent transmission event from its natural reservoir followed by sustained human-to-human infections. It has been reported that the EBOV genome variation might have an effect on the efficacy of sequence-based virus detection and candidate therapeutics.

When Ebola broke out in West Africa in December 2013, triggering the largest-ever epidemic of the disease, there was no vaccine or drug that had been shown to be safe and effective in people. Just 20 months later, a vaccine seems to confer total protection against infection, according to the preliminary results of a trial in Guinea.

Original Source

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination.

Global vaccine-development fund could save thousands of lives, billions of dollars

Pages